The global point-of-care testing (POCT) market is driven by rising patient demand, technological innovation, and supportive regulatory frameworks. Rapid diagnostics, enhanced chronic disease ...
WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (LMDX), a next-generation point of care diagnostics company, today announced findings from its second annual “Point of Care ...
Point of Care Testing (POCT): defined as medical diagnostic testing at or near the point of care-that is, at the time and place of patient care.[1][2] This contrasts with the historical pattern in ...
ED professionals are required to deal with uncertainty on a daily basis. Various tests must be provided to patients with diffuse symptoms, extending waiting times for lab results, overcrowding wards ...
Point-of-care (POC) testing with screen-printed electrodes allows rapid testing of populations for viral outbreaks – at affordable costs, without the need for trained specialists and/or complicated ...
COVID-19 has driven an uptick in healthcare delivery approaches like telemedicine and point-of-care, home, and direct-to-consumer testing, a shift that some observers believe could continue to ...
Point-of-care-testing for suspected COVID-19 reduces time to results and may improve infection control, suggesting these tests might have clinical advantages over widely used laboratory PCR methods.
LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: ...
Point of Care Testing (POCT): defined as medical diagnostic testing at or near the point of care-that is, at the time and place of patient care.[1][2] This contrasts with the historical pattern in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results